Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Acasti Pharma Inc. (ACST) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/10/2023 D Form D - Notice of Exempt Offering of Securities:
10/06/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/25/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2023 8-K Quarterly results
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/24/2023 8-K Quarterly results
07/18/2023 4 Derby Michael (Director) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 12,500 options to buy @ $2.64, valued at $33k
07/18/2023 4 Kavuru Vimal (Director) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 12,500 options to buy @ $2.64, valued at $33k
07/18/2023 4 Olds Donald (Director) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 12,500 options to buy @ $2.64, valued at $33k
07/18/2023 4 Macdonald R. Loch (Chief Medical Officer) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 60,000 options to buy @ $2.64, valued at $158.4k
07/18/2023 4 D'Andrea Carrie (VP Clinical Operations) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 42,000 options to buy @ $2.64, valued at $110.9k
07/18/2023 4 Kumar Amresh (VP Program Management) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 42,000 options to buy @ $2.64, valued at $110.9k
07/18/2023 4 Kohli Prashant (CEO) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 208,334 options to buy @ $2.64, valued at $550k
07/07/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Articles of Amendment Business Corporations Act Québec Enterprise Number: 1160589793 1 Information about the business ACASTI PHARMA INC. Version of the name of the corporation in any other language other than French, if applicable 1 Amendment to Articles 2.1 Amendment to Name 2.2 Other Amendments See Schedule Attached. 2.3. Date and Time of certificate, if applicable Date: July 10, 2023 Time: 12:01 a.m. 2 Correction of Articles 3 Signature Last name and first name of the authorized officer or director: Prashant Kohli Electonic signature of: Prashant Kohli Reserved for the administration Reference number of request: 020200103314688 Numeric designation: LEGAL_1:80872475.2 SCHEDULE TO ARTICLES OF AMENDMENT OF ACASTI PHARMA INC. As of the date of the issuance of a Certificate of Amendme...",
"Acasti Pharma Announces 1-for-6 Reverse Stock Split LAVAL, Québec, July 7, 2023 -- Acasti Pharma Inc. , a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage , today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares. The reverse stock split will become effective July 10, 2023 at 12:01 a.m. ET. The Company's common shares will trade on a split-adjusted basis on The NASDAQ Capital Market, as of the opening of trading on Monday, July 10, 2023. The new CUSIP number for the Company's common shares will be 00430K865. The reverse stock split is being affected as part of the Company's plan to regain compl..."
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/26/2023 3 Macdonald R. Loch (Chief Medical Officer) has filed a Form 3 on Acasti Pharma Inc.
05/18/2023 3 D'Andrea Carrie (VP Clinical Operations) has filed a Form 3 on Acasti Pharma Inc.
05/18/2023 3 Kumar Amresh (VP Program Management) has filed a Form 3 on Acasti Pharma Inc.
05/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Acasti Announces Appointment of Prashant Kohli as CEO",
"Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND Company expects the first patient to be enrolled during the second half of 2023"
03/31/2023 8-K Resignation/termination of a director
03/13/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange Acasti also confirms no exposure to Silicon Valley Bank or Silvergate Bank LAVAL, Québec, March 13, 2023 – Acasti Pharma Inc. a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange . The delisting from the TSXV will not affect the Company’s listing on the NASDAQ Capital Market . The common shares will continue to trade on the NASDAQ under the symbol “ACST”. The Company believes that the trading volume of its shares on the TSXV no longer justifies the e..."
02/14/2023 8-K Quarterly results
02/14/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/25/2023 8-K Other Events  Interactive Data
12/28/2022 8-K Other Events  Interactive Data
12/22/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Acasti Pharma Reports Second Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, November 14, 2022 -- Acasti Pharma Inc. , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the second quarter ended September 30, 2022. Recent Highlights • The Company expects to receive guidance from the Food and Drug Administration on its proposed phase 3 study design for GTX-104 in the form of a Type C meeting by the end of 2022 or early in the first calendar quarter of 2023. This FDA guidance should allow the Company to initiate the Phase 3 safety study and begin enrolling the first patients as planned in the first half ..."
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/30/2022 4 Kavuru Vimal (Director) has filed a Form 4 on Acasti Pharma Inc.
Txns: Granted 45,000 options to buy @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy